{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:40:48Z","timestamp":1774885248816,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05410-6","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T10:06:18Z","timestamp":1735207578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-1166","authenticated-orcid":false,"given":"Marco","family":"Finati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ricapito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"d\u2019Altilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Naspro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Bettocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"issue":"1","key":"5410_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"5410_CR2","doi-asserted-by":"publisher","first-page":"S0302","DOI":"10.1016\/j.eururo.2024.07.027","volume":"17","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O et al (2024) European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (TaT1 and Carcinoma in Situ)-A Summary of the 2024 guidelines Update. Eur Urol. Published Online August 17(24):S0302\u20132838. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","journal-title":"Published Online August"},{"issue":"5","key":"5410_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","volume":"466","author":"E Comp\u00e9rat","year":"2015","unstructured":"Comp\u00e9rat E, Larr\u00e9 S, Roupret M et al (2015) Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch Int J Pathol 466(5):589\u2013594. https:\/\/doi.org\/10.1007\/s00428-015-1739-2","journal-title":"Virchows Arch Int J Pathol"},{"issue":"4","key":"5410_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V et al (2021) European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder Cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for Grade: an update from the EAU NMIBC guidelines Panel. Eur Urol 79(4):480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"issue":"1","key":"5410_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L et al (2016) EORTC nomograms and Risk groups for Predicting recurrence, progression, and Disease-specific and overall survival in Non-muscle-invasive Stage Ta-T1 urothelial bladder Cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol 69(1):60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"issue":"3","key":"5410_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S van den Bosch","year":"2011","unstructured":"van den Bosch S, Alfred Witjes J (2011) Long-term Cancer-specific survival in patients with High-risk, non\u2013muscle-invasive bladder Cancer and Tumour Progression: a systematic review. Eur Urol 60(3):493\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.045","journal-title":"Eur Urol"},{"issue":"1","key":"5410_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Hensley PJ, Bree KK et al (2022) Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder Cancer treated with Bacillus Calmette-Gu\u00e9rin. Eur Urol Oncol 5(1):84\u201391. https:\/\/doi.org\/10.1016\/j.euo.2021.11.006","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"5410_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/cancers16091684","volume":"16","author":"A \u015alusarczyk","year":"2024","unstructured":"\u015alusarczyk A, Garbas K, Pustu\u0142a P, Zapa\u0142a \u0141, Radziszewski P (2024) Assessing the predictive accuracy of EORTC, CUETO and EAU Risk Stratification models for High-Grade recurrence and progression after Bacillus Calmette-Gu\u00e9rin therapy in non-muscle-invasive bladder Cancer. Cancers 16(9):1684. https:\/\/doi.org\/10.3390\/cancers16091684","journal-title":"Cancers"},{"issue":"7\u20138","key":"5410_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1159\/000506238","volume":"104","author":"G Chen","year":"2020","unstructured":"Chen G, Yang T, Shao Q et al (2020) Sub-staging-specific differences in Recurrence-Free, Progression-Free, and Cancer-Specific Survival for patients with T1 bladder Cancer: a systematic review and Meta-analysis. Urol Int 104(7\u20138):580\u2013586. https:\/\/doi.org\/10.1159\/000506238","journal-title":"Urol Int"},{"issue":"6","key":"5410_CR10","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.juro.2012.11.120","volume":"189","author":"M Roupr\u00eat","year":"2013","unstructured":"Roupr\u00eat M, Seisen T, Comp\u00e9rat E et al (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol 189(6):2069\u20132076. https:\/\/doi.org\/10.1016\/j.juro.2012.11.120","journal-title":"J Urol"},{"key":"5410_CR11","doi-asserted-by":"publisher","unstructured":"Lopez-Beltran A, Raspollini MR, Hansel D et al (2024) International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer. Am J Surg Pathol.;48(1):e24-e31. https:\/\/doi.org\/10.1097\/PAS.0000000000002121","DOI":"10.1097\/PAS.0000000000002121"},{"issue":"6","key":"5410_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Foerster B, Catto JWF et al (2018) Repeat Transurethral Resection in non-muscle-invasive bladder Cancer: a systematic review. Eur Urol 73(6):925\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.014","journal-title":"Eur Urol"},{"issue":"12","key":"5410_CR13","doi-asserted-by":"publisher","first-page":"e0189354","DOI":"10.1371\/journal.pone.0189354","volume":"12","author":"BS Tae","year":"2017","unstructured":"Tae BS, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH (2017) Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. PLoS ONE 12(12):e0189354. https:\/\/doi.org\/10.1371\/journal.pone.0189354","journal-title":"PLoS ONE"},{"issue":"1","key":"5410_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000535024","volume":"108","author":"Y Volz","year":"2023","unstructured":"Volz Y, Trappmann R, Ebner B et al (2023) Upstaging after Transurethral Resection of the bladder for Non-muscle-invasive Cancer of the bladder: who is at highest risk? Urol Int 108(1):42\u201348. https:\/\/doi.org\/10.1159\/000535024","journal-title":"Urol Int"},{"issue":"2","key":"5410_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","volume":"61","author":"BWG van Rhijn","year":"2012","unstructured":"van Rhijn BWG, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61(2):378\u2013384. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.026","journal-title":"Eur Urol"},{"issue":"10","key":"5410_CR16","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1007\/s00345-021-03690-w","volume":"39","author":"B Cal\u00f2","year":"2021","unstructured":"Cal\u00f2 B, Sanguedolce F, Falagario UG et al (2021) Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary? World J Urol 39(10):3815\u20133821. https:\/\/doi.org\/10.1007\/s00345-021-03690-w","journal-title":"World J Urol"},{"issue":"4","key":"5410_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"R J\u00e4rvinen","year":"2015","unstructured":"J\u00e4rvinen R, Marttila T, Kaasinen E et al (2015) Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Gu\u00e9rin (BCG) or alternating BCG and interferon-\u03b12b instillations: prospective randomised FinnBladder-4 study. Eur Urol 68(4):611\u2013617. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.022","journal-title":"Eur Urol"},{"issue":"6","key":"5410_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.euf.2023.04.012","volume":"9","author":"P Nurminen","year":"2023","unstructured":"Nurminen P, Nummi A, Kesti O et al (2023) Comparison of Bacillus Calmette-Gu\u00e9rin Maintenance Therapy with monthly instillations and the Southwest Oncology Group Protocol in the treatment of non-muscle-invasive bladder Cancer. Eur Urol Focus 9(6):1000\u20131007. https:\/\/doi.org\/10.1016\/j.euf.2023.04.012","journal-title":"Eur Urol Focus"},{"issue":"1","key":"5410_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4132\/jptm.2023.12.11","volume":"58","author":"B Choy","year":"2024","unstructured":"Choy B, Tretiakova M, Zynger DL (2024) What\u2019s new in genitourinary pathology 2023: WHO 5th edition updates for urinary tract, prostate, testis, and penis. J Pathol Transl Med 58(1):45\u201348. https:\/\/doi.org\/10.4132\/jptm.2023.12.11","journal-title":"J Pathol Transl Med"},{"issue":"1","key":"5410_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","volume":"82","author":"M Roumigui\u00e9","year":"2022","unstructured":"Roumigui\u00e9 M, Kamat AM, Bivalacqua TJ et al (2022) International bladder Cancer Group Consensus Statement on Clinical Trial Design for patients with Bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder Cancer. Eur Urol 82(1):34\u201346. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.005","journal-title":"Eur Urol"},{"issue":"6","key":"5410_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bju.16293","volume":"133","author":"R Contieri","year":"2024","unstructured":"Contieri R, Tan WS, Grajales V et al (2024) Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int 133(6):733\u2013741. https:\/\/doi.org\/10.1111\/bju.16293","journal-title":"BJU Int"},{"issue":"3","key":"5410_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/cancers15030934","volume":"15","author":"M Valeri","year":"2023","unstructured":"Valeri M, Contieri R, Fasulo V et al (2023) Prospective validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: results from a Mono-Institutional Confirmatory Analysis in BCG treated patients. Cancers 15(3):934. https:\/\/doi.org\/10.3390\/cancers15030934","journal-title":"Cancers"},{"issue":"3","key":"5410_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/JU.0000000000001422","volume":"205","author":"FC de Jong","year":"2021","unstructured":"de Jong FC, Hoedemaeker RF, Kvikstad V et al (2021) T1 substaging of nonmuscle invasive bladder Cancer is Associated with bacillus Calmette-Gu\u00e9rin failure and improves patient stratification at diagnosis. J Urol 205(3):701\u2013708. https:\/\/doi.org\/10.1097\/JU.0000000000001422","journal-title":"J Urol"},{"issue":"1","key":"5410_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.euf.2016.06.004","volume":"4","author":"R Colombo","year":"2018","unstructured":"Colombo R, Hurle R, Moschini M et al (2018) Feasibility and clinical roles of different Substaging systems at First and Second Transurethral Resection in patients with T1 high-Grade bladder Cancer. Eur Urol Focus 4(1):87\u201393. https:\/\/doi.org\/10.1016\/j.euf.2016.06.004","journal-title":"Eur Urol Focus"},{"issue":"4","key":"5410_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.euo.2022.05.001","volume":"5","author":"A Gallioli","year":"2022","unstructured":"Gallioli A, Diana P, Fontana M et al (2022) En Bloc Versus Conventional Transurethral resection of bladder tumors: a single-center prospective randomized noninferiority trial. Eur Urol Oncol 5(4):440\u2013448. https:\/\/doi.org\/10.1016\/j.euo.2022.05.001","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"5410_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.eururo.2024.04.015","volume":"86","author":"J Yuen-Chun Teoh","year":"2024","unstructured":"Yuen-Chun Teoh J, Cheng CH, Tsang CF et al (2024) Transurethral En Bloc Resection Versus Standard Resection of bladder tumour: a Randomised, Multicentre, Phase 3 Trial. Eur Urol 86(2):103\u2013111. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.015","journal-title":"Eur Urol"},{"issue":"1","key":"5410_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bju.13354","volume":"118","author":"P Gontero","year":"2016","unstructured":"Gontero P, Sylvester R, Pisano F et al (2016) The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette-Gu\u00e9rin. BJU Int 118(1):44\u201352. https:\/\/doi.org\/10.1111\/bju.13354","journal-title":"BJU Int"},{"key":"5410_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fonc.2019.00465","volume":"9","author":"B Cal\u00f2","year":"2019","unstructured":"Cal\u00f2 B, Chirico M, Fortunato F et al (2019) Is repeat transurethral resection always needed in high-Grade T1 bladder Cancer? Front Oncol 9:465. https:\/\/doi.org\/10.3389\/fonc.2019.00465","journal-title":"Front Oncol"},{"issue":"4","key":"5410_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3390\/cancers14040887","volume":"14","author":"F Del Giudice","year":"2022","unstructured":"Del Giudice F, Flammia RS, Chung BI et al (2022) Compared efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for high-risk non-muscle invasive bladder Cancer (NMIBC): a propensity score matched analysis. Cancers 14(4):887. https:\/\/doi.org\/10.3390\/cancers14040887","journal-title":"Cancers"},{"key":"5410_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.euros.2023.11.003","volume":"59","author":"C Nardelli","year":"2024","unstructured":"Nardelli C, Aveta A, Pandolfo SD et al (2024) Microbiome profiling in bladder Cancer patients using the First-morning urine sample. Eur Urol Open Sci 59:18\u201326. https:\/\/doi.org\/10.1016\/j.euros.2023.11.003","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"5410_CR31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00345-019-02936-y","volume":"38","author":"M Kardoust Parizi","year":"2020","unstructured":"Kardoust Parizi M, Enikeev D, Glybochko PV et al (2020) Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. World J Urol 38(6):1437\u20131449. https:\/\/doi.org\/10.1007\/s00345-019-02936-y","journal-title":"World J Urol"},{"key":"5410_CR32","doi-asserted-by":"publisher","unstructured":"Kl\u00e4ger J, Koeller MC, Oszwald A, Wasinger G, D\u2019Andrea D, Comp\u00e9rat E (2024) A single-center retrospective comparison of pT1 substaging methods in bladder cancer. Virchows Arch Published Online September 2. https:\/\/doi.org\/10.1007\/s00428-024-03907-4","DOI":"10.1007\/s00428-024-03907-4"},{"issue":"6","key":"5410_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000514759","volume":"99","author":"F Sanguedolce","year":"2021","unstructured":"Sanguedolce F, Cal\u00f2 B, Mancini V et al (2021) Non-muscle invasive bladder Cancer with variant histology: biological features and clinical implications. Oncology 99(6):345\u2013358. https:\/\/doi.org\/10.1159\/000514759","journal-title":"Oncology"},{"issue":"8","key":"5410_CR34","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.urolonc.2014.05.008","volume":"32","author":"HS Kim","year":"2014","unstructured":"Kim HS, Kim M, Jeong CW, Kwak C, Kim HH, Ku JH (2014) Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol 32(8):1191\u20131199. https:\/\/doi.org\/10.1016\/j.urolonc.2014.05.008","journal-title":"Urol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05410-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:02:22Z","timestamp":1767996142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05410-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5410"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05410-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients were retrospectively enrolled after this study was approved by IRB of Policlinico Riuniti of Foggia on 15th of March 2022 (Approval Code 31\/CE\/2022). An institutional review board waiver for informed consent was obtained prior to conducting this study, in accordance with institutional regulations when dealing with de-identified previously collected data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}},{"value":"None of the authors have any relevant disclosures, and none of the authors have any financial or non-financial interests that may be relevant to the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"47"}}